On July 3, China’s National Medical Products Administration (NMPA) officially approved Gensci Pharma’s Class 1 innovative drug—fusincimab (brand name: Jinbeixin®). As China’s first independently ...
In the drug development ecosystem, a long-standing “valley of death” exists between basic research discoveries and approved therapies, where many potential candidates stall due to translational barr...
Ophthalmology stands at the forefront of gene therapy translation. The retina’s immune-privileged status, anatomically confined structure, and objectively quantifiable visual endpoints have made the ...
